Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence PR Newswire LUND, Sweden, March 26...
Swissmedic approves Buvidal for the treatment of opioid dependence PR Newswire LUND, Sweden, Dec. 18, 2020 LUND, Sweden, Dec. 18, 2020...
Positive Results From Phase 2 Study of Once-weekly FluidCrystal® Formulation of Setmelanotide in Healthy Volunteers With Obesity PR...
Camurus Raises Full Year 2020 Revenue Guidance PR Newswire LUND, Sweden, June 23, 2020 LUND, Sweden, June 23, 2020 /PRNewswire/ -- Camurus today...
Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US PR Newswire LUND...
Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid Dependence PR Newswire LUND, Sweden, May 14, 2020 Buvidal® (buprenorphine...
Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid Dependence Buvidal® (buprenorphine) prolonged release injection receives...
Camurus' Interim Report January-March 2020 PR Newswire STOCKHOLM, May 7, 2020 STOCKHOLM, May 7, 2020 /PRNewswire/ -- "The number of patients...
Camurus Announces Strong First Quarter Demand for Buvidal® PR Newswire Lund, Sweden, April 2, 2020 Large increase in the number of patients...
Camurus Announces Strong First Quarter Demand for Buvidal® - Large increase in the number of patients treated with weekly and monthly Buvidal®...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.